Wegovy price in South Africa: how the cost is set and why it has fallen

What does Wegovy cost per month in 2026?

After the March 2026 reductions, Reuters reported the lowest Wegovy dose at R1,873 per month, down from R3,090, and the highest dose down 27% to R3,746 per month. A further 12% cut to the 1.7 mg dose was awaiting approval at the time of the announcement.

These are the manufacturer's announced prices. What you pay at the till includes the pharmacy's dispensing fee, so reported shelf prices for the maintenance dose cluster roughly between R2,800 and R4,200 depending on the pharmacy. Prices vary by pharmacy and dose; confirm with your pharmacy before you budget.

South Africa's medicine pricing system helps here. Private-sector medicines sell under a regulated Single Exit Price: every pharmacy buys the medicine at the same price, and the only legal difference between pharmacies is the capped dispensing fee. That is why quotes differ by hundreds of rand, not thousands, and why phoning around is worth ten minutes of your time.

Wegovy price in South Africa by dose

Wegovy steps up through five dose strengths over about four months, and the monthly cost steps up with it. Here is the price picture as reported in mid-2026:

One pen holds four weekly doses, so a pen is roughly a month of treatment. The early months cost less because you start on the cheapest dose, which softens the first part of the budget.

How the dose steps drive what you pay

Wegovy's five strengths each come as their own pen, and one pen holds four weekly doses. While you climb the schedule you buy a different strength roughly each month, so the amount you pay changes four times before maintenance, without any price list changing at all.

The steps are not optional. They exist so the body can adjust, and jumping ahead to shorten the ladder usually means worse nausea, which is why a doctor will not authorise it as a savings plan.

Three practical points follow for the budget. A pen cannot be stretched: it delivers its labelled dose, and altering doses to make a pen last longer changes the treatment a doctor confirmed. Cold-chain pens cannot be returned, so a dose change mid-pen can strand doses you have paid for, which is why changes are usually timed to pen boundaries. And some people stay longer on a middle step when it is working and well tolerated; where that is the doctor's call, it also happens to cost less than the top dose.

The pattern to avoid is stop-start treatment driven by money. Restarting after a long gap often means stepping up from a lower dose again, which pays for titration twice. If cost is squeezing you, raise it at a review rather than rationing doses.

One pen, four doses also means partial months do not exist: you cannot buy two weeks of medicine at a time, so plan refill timing around your reviews to avoid paying for a pen you may not finish.

Why the shelf price differs from the announced price

Manufacturer announcements describe the regulated price the company charges, the Single Exit Price, which already includes a logistics fee for distribution. The pharmacy then adds a dispensing fee, capped in tiered bands under the pricing regulations, and shelf quotes include VAT. Those layers are the whole gap between a press release and a till slip.

You can verify any quote yourself. The Department of Health publishes every registered medicine's Single Exit Price in the Medicine Price Registry at mpr.gov.za. A quote far above the registry price plus a reasonable fee deserves a query; one far below it is a warning, because legitimate pharmacies cannot sell below the regulated chain's cost.

The yearly rhythm is regulated too. Manufacturers may only raise prices by the annual adjustment the health department approves, reported by Daily Maverick at a maximum of 1.47% for 2026, down from 5.25% in 2025. Cuts follow their own track: a manufacturer that wants to charge less notifies the regulator first, which is why the March 2026 reduction to the 1.7 mg dose was described as awaiting approval rather than immediate. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

How has the Wegovy price changed since launch?

Wegovy launched in South Africa in August 2025 at prices widely criticised as out of reach for most households. Within eight months the price had been cut twice.

The first reduction came in December 2025. The second, in March 2026, was the bigger move: the starting dose fell by close to 40%, from R3,090 to R1,873, and the top dose fell 27% to R3,746. If you saw a Wegovy quote in 2025, it is out of date.

The direction of travel matters if you are planning long-term treatment. Obesity care runs over years, not weeks, so a price that keeps easing changes the total cost of treatment far more than any single month's saving.

Why did the Wegovy price drop in 2026?

Competition, mainly. Mounjaro (tirzepatide) launched in South Africa about eight months before Wegovy, and the two now compete directly in the same market. Novo Nordisk cut Wegovy's South African price in December 2025 and again in March 2026, saying its initial pricing approach was not aligned with market conditions.

For anyone comparing options, that rivalry has been good news: both medicines are meaningfully cheaper than the first wave of GLP-1 pricing here. Our guide to GLP-1 treatment costs in South Africa puts all the current numbers side by side.

Demand explains why the market matters so much. Spotlight reported that semaglutide jumped from 170th to 12th among the biggest medicine spending drivers tracked by one claims processor between 2023 and 2024, and that sales kept climbing through 2025. A market that size attracts competitors, and competitors move prices.

Will generic competition change the Wegovy price?

It is already reshaping the market around it. SAHPRA approved South Africa's first generic semaglutide injection, from Sun Pharma, in July 2026. That product is registered for type 2 diabetes, not weight management, so it is not a generic Wegovy, but it introduces cheaper semaglutide into the same supply chain and the same pricing conversations.

The wider backdrop points the same way. Reuters tied the generic's timing to the expiry of Novo Nordisk's local semaglutide patent in March 2026, and reported that Mounjaro held just over half of the South African GLP-1 market by the end of January 2026. Spotlight reported analysts expecting generic semaglutide to reach South Africa around 2027; the first approval arrived ahead of that.

None of it guarantees another Wegovy cut, and no further reduction had been announced at the time of writing. But two price cuts in eight months happened under exactly this kind of pressure, so the direction of travel favours lower prices.

What generic competition does not change: no generic is registered for weight management in South Africa, and any product marketed that way outside a licensed pharmacy is unregistered. A doctor's assessment and a licensed pharmacy remain the only route.

What does a year on Wegovy add up to?

Using the reported mid-2026 figures, the first four months on escalating doses cost less than maintenance, and from month five you pay the 2.4 mg price. At about R3,746 per month, a full year at maintenance works out to roughly R45,000 before any consultation fees, and the true first-year figure is lower because of the cheaper starting doses.

Budget for the medicine plus the medical care around it: an initial doctor assessment, follow-up reviews, and in some cases blood tests. Consultation fees are set by each practice and sit separately from what any pharmacy charges for medication, so when comparing the true cost of treatment, ask about the full course of reviews rather than only the first visit.

One smaller item rounds out the budget: pen needles and a sharps container cost a modest amount each month if your pharmacy does not include them. Storage is the other quiet cost factor, covered below.

Storing pens so you do not lose money

Every pen is a cold-chain product that cannot be returned, so storage is part of the budget. Unopened pens stay in the fridge at 2 to 8 degrees, in the original carton. Once a pen is in use, the product information allows it out of the fridge below 30 degrees for a set number of weeks; the exact window is printed in the leaflet in your pack, so check it and note the date of first use.

Load shedding rarely threatens pens inside those rules. A closed fridge holds its temperature for hours, and an in-use pen is fine in a room under 30 degrees. The two real risks are freezing and heat: a pen that touches a freezer plate or an ice brick directly must be discarded, and a pen left in a hot car can quietly pass 30 degrees. Neither kind of damage is visible.

Courier deliveries deserve attention in summer: unpack immediately and refrigerate. For flights, pens travel in hand luggage in an insulated pouch, never in the hold. Simple habits, but each one protects a pen you have already paid for.

Does medical aid pay for Wegovy in South Africa?

Usually not. Obesity is not a Prescribed Minimum Benefit condition, so schemes are not obliged to fund weight-loss medication, and most open schemes list it as an exclusion. Some plans let you pay from a medical savings account, which spends your own funds rather than scheme risk cover.

The exception runs through diagnosis. Where a doctor is treating a registered condition such as type 2 diabetes, different funding rules can apply, but that is a clinical decision about a different medicine and indication, not a route to cheaper Wegovy.

A few schemes are reviewing their position as the evidence base grows, so it is worth a call to your scheme with the medicine name and NAPPI code. Our medical aid guide covers scheme-by-scheme detail and what to ask.

What should a motivation letter to your scheme cover?

Where a scheme leaves any door open, the document that opens it is a clinical motivation from your doctor, not a letter from you. It should answer the scheme's criteria point by point: the diagnosis and its code, body measurements over time, blood results, related conditions such as high blood pressure or sleep apnoea, what has been tried already and the clinical reasoning for the treatment plan.

Do the groundwork first. Ask the scheme in writing whether your plan has any benefit for weight management and exactly what documentation it wants, then include the medicine's NAPPI code, which your pharmacy can supply. If the answer is yes in principle, expect a pre-authorisation step before anything is paid.

Keep expectations realistic: because obesity is not a Prescribed Minimum Benefit, a scheme can decline even a strong letter, and success more often unlocks savings-account payment or a plan-specific benefit than open risk cover. Keep any decline in writing; some schemes allow appeals, and criteria change from year to year.

How does the Wegovy price compare with Ozempic and Mounjaro?

At maintenance doses the registered once-weekly options land in a broadly similar band of a few thousand rand per month, and all have seen price movement through 2025 and 2026. Exact comparisons shift with each price change and each pharmacy's fees, so treat any static comparison table you find online as a snapshot, not a promise.

Remember that Ozempic is registered for type 2 diabetes, not weight management, so a like-for-like comparison is not just about rands. See how much Ozempic is in South Africa for that side of the picture, and our Wegovy availability guide for what is actually on SA shelves.

Can you pay less for Wegovy, safely?

Yes, within limits. Phone two or three pharmacies, including independents and courier pharmacies, because dispensing fees differ. Timing matters too: prices have moved down twice in under a year, so recheck before assuming an old quote still holds.

Dose also drives cost, but that decision belongs to your doctor. Some people maintain well on 1.7 mg rather than 2.4 mg, and where that is clinically sound it happens to cost less. What a doctor will not do is pick a dose to fit a budget at the expense of the treatment working.

What not to do: unregistered online sellers, imported pens without paperwork, or compounded "semaglutide" from beauty clinics. SAHPRA has warned about these products, their contents are unverified, and buying a Schedule 4 medicine without a doctor's authorisation is illegal in South Africa.

Cost is also not the only consideration. Wegovy commonly causes nausea, diarrhoea, constipation and stomach discomfort, especially at dose increases, and it is not suitable in pregnancy or for people with a personal or family history of medullary thyroid cancer or MEN2. A doctor weighs suitability before cost even becomes the question, and severe persistent stomach pain on treatment means seek medical care immediately.

Frequently asked questions